Biora Therapeutics (BIOR) Proxy Filing summary

Executive summary

• Special Meeting scheduled for October 9, 2024, to address urgent compliance with Nasdaq listing requirements.

• Proposals include a reverse stock split, reduction in authorized shares, and potential adjournment to solicit more proxies.

• Board recommends voting in favor of all proposals to maintain listing and provide future flexibility.

• Forward-looking statements highlight risks and uncertainties, especially regarding Nasdaq compliance.

Voting matters and shareholder proposals

• Proposal 1: Approve a reverse stock split at a ratio between 3:1 and 15:1 to increase share price and maintain Nasdaq listing.

• Proposal 2: Approve a reduction in authorized shares, contingent on Proposal 1, to avoid an excessive number of unissued shares.

• Proposal 3: Approve adjournment of the meeting if more time is needed to solicit proxies.

• Board recommends voting FOR all proposals.

• No other matters are currently expected, but proxies may vote on additional items if they arise.

Board of directors and corporate governance

• Board has discretion to select the reverse split ratio and implement or abandon amendments after shareholder approval.

• No officer or director has a substantial interest in the proposals beyond that of all shareholders.

• Board members and executive officers collectively own just over 51% of outstanding shares.